The deal hands Lilly a medicine could “shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,” one of its executives said in a statement.Dive Brief:Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers […]
